PharmaTech LLC of Davie, FL, the manufacturer of the Rugby®-branded product, is voluntarily recalling all lots within the expiry of Diocto Liquid, a docusate sodium solution due to a risk of product contamination with Burkholderia cepacia. Use of docusate sodium liquid contaminated with B. cepacia may result in serious infections that could be life-threatening in patients with compromised immune systems and in patients with chronic lung conditions such as cystic fibrosis.
As part of its commitment to patient safety, Rugby® Laboratories is working with PharmaTech LLC to notify customers who may be in possession of Diocto Liquid NDC 0536-0590-85; 50 mg/5 mL for all lots within the expiration period.
Diocto Liquid is used as a stool softener and is packaged in one pint (473 mL) bottles. All lots with NDC 0536-0590-85 are included in the recall. Diocto Liquid was distributed nationwide to wholesale and retail facilities including hospitals and pharmacies. The company learned of the potential issue through the receipt of two isolated complaints regarding this product. FDA has informed PharmaTech and Rugby that it received several adverse event reports of B. cepacia infections in patients. Additionally, some of these reports identify liquid docusate products manufactured by companies other than PharmaTech.
PharmaTech is notifying its distributors and customers by recall letter and is arranging for return of all recalled products. Consumers, pharmacies, and healthcare facilities that have product which is being recalled should stop using and dispensing them immediately.
This recall is being conducted with the full knowledge of the U.S. Food and Drug Administration.
To read the original press release on the FDA’s website, click here.
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
